News - The Medicines Company

Filter

Current filters:

The Medicines Company

Popular Filters

Promising future for Cubist's Sivextro in anti-MRSA sector

04-04-2014

Following its launch, Cubist Pharmaceutical’s second generation oxazolidinone Sivextro Sivextro will…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDalvanceDurata TherapeuticsMarkets & MarketingoritavancinPharmaceuticalSivextroThe Medicines Company

FDA accepts The Medicines Company's NDA for oritavancin with priority review

FDA accepts The Medicines Company's NDA for oritavancin with priority review

19-02-2014

The US Food and Drug Administration has accepted the filing of The Medicines Company’s New Drug Application…

Antibiotics and Infectious diseasesNorth AmericaoritavancinPharmaceuticalRegulationThe Medicines CompanyUSA

FDA advisory committee votes against approval of antiplatelet therapy cangrelor

FDA advisory committee votes against approval of antiplatelet therapy cangrelor

13-02-2014

The US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted yesterday…

cangrelorCardio-vascularPharmaceuticalRegulationThe Medicines CompanyUSA

The Medicines Company acquires antibiotics maker Rempex Pharma

04-12-2013

USA-based The Medicines Company has acquired Rempex Pharmaceuticals, a company with multiple potential…

Antibiotics and Infectious diseasesMergers & AcquisitionsPharmaceuticalRempex PharmaceuticalsThe Medicines Company

Vectura anticipates potential royalty and milestone payments on Fibrocaps

06-08-2013

UK-based developer of inhaled therapies Vectura (LSE: VEC) confirms that the completion of the acquisition…

FibrocapsFinancialPharmaceuticalProFibrixResearchThe Medicines CompanyVectura

The Medicines Co to acquire ProFibrix but deal hinges on trial results

05-06-2013

US drugmaker The Medicines Company (Nasdaq: MDCO) says it has reached agreement to acquire all of the…

BiotechnologyFibrocapsMergers & AcquisitionsPharmaceuticalProFibrixThe Medicines Company

Swedish registry questions superiority of bivalirudin over heparin in patients undergoing PCI for NSTE-ACS

22-05-2013

Results from a large observational study reported at EuroPCR 2013 (the official annual meeting of the…

AngiomaxbivalirudinCardio-vascularheparinPharmaceuticalResearchThe Medicines Company

The Medicines Company gets rights to Alnylam's PCSK9 inhibitors program for cholesterol

05-02-2013

USA-based The Medicines Company (Nasdaq: MDCO) has formed an exclusive global alliance with RNAi therapeutics…

Alnylam PharmaceuticalsAngiomaxBiotechnologyCardio-vascularLicensingPharmaceuticalThe Medicines Company

The Medicines Company expands into Russian pharmaceutical market

14-06-2012

US drugmaker The Medicines Company (Nasdaq: MDCO) is expanding into Russia, through the start of sales…

AngioxCardio-vascularEuropeMarkets & MarketingPharmaceuticalThe Medicines Company

AstraZeneca CEO to go early, as 1st-qtr sales and profits plunge; makes deal with TMC for cardiovasculars

26-04-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) stunned the markets this morning, announcing that its…

AstraZenecaCardio-vascularFinancialLicensingManagementPharmaceuticalThe Medicines Company

The Medicines Co settles with APP over Angiomax

24-01-2012

The Medicines Company (Nasdaq: MDCO) says that it has settled the law suits filed by company in the US…

AngiomaxAPP PharmaceuticalsCardio-vascularFresenius KabiGenericsLegalNorth AmericaPatentsPharmaceuticalThe Medicines Company

MedicinesCo takes equity stake in GeNO, gaining access to nitric oxide platforms

06-12-2011

USA-based The Medicines Company (Nasdaq: MDCO) says it has acquired a non-controlling equity investment…

GeNOLicensingMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryThe Medicines Company

UK’s NICE backs use of TMC’s Angiox for STEMI patients undergoing primary PCI

27-07-2011

Following a previous positive draft guidance, the UK drugs watch dog the National Institute for Health…

AngioxCardio-vascularEuropePharmaceuticalPricingRegulationThe Medicines Company

Back to top